Proprietary chemistry allows aryl nitriles to participate in cross coupling reactions to produce derivatives useful in the manufacture of drugs and drug intermediates
Pharmacore has reached an agreement with DSM Pharma Chemicals Venlo to license aryl nitrile based cross coupling technology. This proprietary chemistry allows a wide variety of aryl nitriles to participate in cross coupling reactions to produce derivatives that are very useful in the manufacture of drugs and drug intermediates, including unsymmetrical biaryls, styrenes, alkylated aromatics, and alkynylated aromatics.
Pharmacore says it will immediately apply this new technology to its molecular building block business, producing novel building blocks that are not currently available elsewhere or those that would be considerably more expensive if produced via traditional means. "This technology will give PharmaCore a distinct advantage in the production of certain building block targets relative to current aryl halide based methodology," said Joe Miller, vice president of chemistry at Pharmacore.
"In particular, certain classes of aryl nitriles are significantly less expensive than the corresponding aryl halides giving Pharmacore a real economic edge with respect to our competitors in the preparation of these target blocks."
